Joseph Wolk on earnings per share
From Johnson & Johnson ($JNJ) Q1 2026 Earnings Call · · Castify Earnings Call
“We are increasing our guidance by $0.02 to a range of $11.30 to $11.50, representing 5.7% growth at the midpoint. As such, we now expect reported adjusted earnings per share of $11.55 at the midpoint or a growth of 7.1%.”
On , Joseph Wolk, Executive VP & CFO at Johnson & Johnson, spoke about earnings per share during Johnson & Johnson ($JNJ) Q1 2026 Earnings Call on Castify Earnings Call.
About Joseph Wolk
Joseph Wolk, Executive Vice President and CFO of Johnson & Johnson, has been a primary speaker on the company’s recent earnings calls, where he has discussed financial results and guidance. On the Q1 2026 call, Wolk stated the company was increasing its operational sales guidance to a range of 5.9% to 6.9% with a midpoint of $100.2 billion, and raising adjusted earnings per share guidance by $0.02 to a range of $11.30 to $11.50. He noted that the company’s financial calendar for 2026 includes a 53rd week, providing a benefit of approximately 100 basis points. Wolk also said the company was maintaining its guidance for adjusted pre-tax operating margin to improve by at least 50 basis points, driven by operating efficiencies with a portion reinvested to support new product launches. He reported that the company ended Q1 2026 with approximately $22 billion in cash and marketable securities and $55 billion in debt, with free cash flow of approximately $1.5 billion for the quarter, which he attributed to payment timing changes and increased capital expenditures. On prior calls, Wolk addressed the company’s financial outlook and strategic moves. During the Q4 2025 call, he said the company anticipated operational sales growth in the range of 5.7% to 6.7% for 2026 and expected free cash flow generation to rise to approximately $21 billion. He also noted that the company’s 2026 pre-tax operating margin guidance accounted for full-year MedTech tariffs of approximately $500 million and the impact of a voluntary agreement with the US government to improve access to medicines. On the Q3 2025 call, Wolk discussed the planned separation of the orthopedics business, stating the move was expected to enhance strategic and operational focus for each company, with a target completion within 18 to 24 months. He also said the company did not need to rely on large transactions to drive growth, citing momentum in its current portfolio and pipeline.